Cite
HARVARD Citation
Henry, R. et al. (n.d.). Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials. Diabetes, obesity & metabolism. 17 (6), pp. 560-565. [Online].